Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan Combined With Azacitidine and Venetoclax for Older or Unfit Patients With Treatment Naive Acute Myeloid Leukemia
NCT04964505Phase 1Terminated
- Start
- Jul 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of uproleselan in acute myeloid leukemia (AML). Primary endpoints: Incidence of adverse events up to 30 days and Recommended phase II dose. Started Jul 2021; status: terminated.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04964505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964505.